Sangamo Therapeutics Inc. (NASDAQ: SGMO) is one of the best penny stocks under $1 to buy now. On June 24, Sangamo Therapeutics announced positive topline results from its registrational Phase 1/2 ...

On June 24, Sangamo Therapeutics announced positive topline results from its registrational Phase 1/2 STAAR study. This global, open-label, single-dose, dose-ranging, multicenter clinical study ...

Sangamo Therapeutics Inc. (NASDAQ: SGMO) is one of the best penny stocks under $1 to buy now. On June 24, Sangamo Therapeutics announced positive topline results from its registrational Phase 1/2 ...

More information: Ke Wu et al, Genomic insights into cpb2-positive Clostridium perfringens and the potential biological function of cpb2 gene, One Health Advances (2024).

Sensorion Announces Preliminary Positive Data from the First Cohort of the Audiogene Phase 1/2 Gene Therapy Clinical Trial ...

LAS VEGAS — In this Healio Video Perspective from Clinical Trials at the Summit, Christine Kay, MD, discusses phase 1/2 results for OPGx-LCA5, a gene therapy for Leber congenital amaurosis ...

Demonstrated greater α-synuclein reductions compared to other gene therapy approaches LONDON, June 06, 2025 (GLOBE NEWSWIRE) -- Spur Therapeutics today announced positive new preclinical data for ...

Regenxbio Inc.’s gene therapy in treating Duchenne muscular dystrophy (DMD) produced positive initial phase I/II results from its first five patients. However, the company’s stock (NASDAQ:RGNX) ...

Regenxbio Inc.’s gene therapy in treating Duchenne muscular therapy produced positive initial phase I/II results from its first five patients. However, the company’s stock (NASDAQ:RGNX) had shuddered ...

The Tampa Bay Buccaneers have found plaudits few and far between since Baker Mayfield took over from Tom Brady, but all the former first-round pick has done is play good football.

Buccaneers 'Clutch Gene' Part Of Positive 2025 Outlook The Tampa Bay Buccaneers are finally garnering some respect in the league for their exploits in the past two seasons.

On June 2, Needham raised its price target for Taysha Gene Therapies Inc. (NASDAQ:TSHA) to $8 from $6, while maintaining a Buy rating on the stock.